Immunoglobulin cleavage fragment vaccine compositions
OwnerRobert Jordan, David M. Knight +1inventors
InventorsRobert Jordan, David M. Knight, Randall Brezski
Life of this patent
Estimating the term…
Abstract
The invention relates to methods and reagents for the preparation and use of a therapeutic immunospecific for IgG breakdown products retaining antigen binding but having lost effector functions. The reagents of the invention may be used as immunogens for the purpose of prophylactic or therapeutic vaccination of a human subject.
Claims33
A method of protecting a human subject from a pathological condition characterized by the release of a protease, wherein the method comprises administering a peptide immunogen, wherein the peptide is capable of generating antibodies reactive with a proteolytic cleavage site on IgG.
A method of treating a patient, wherein the patient is being treated with a specific antibody-containing composition, wherein antibody is susceptible to cleavage by one or more proteases associated with the specific disease being treated, the method including the step of administering to the patient a peptide immunogen wherein the peptide is a peptide fragment or analogue representative of a proteolytic cleavage site on IgG produced by the one or more proteases associated with the specific disease being treated by antibody therapy.
A vaccine composition comprising a peptide comprising at least 5 contiguous amino acids selected from the human IgG hinge region sequences of SEQ ID NO:
- 1, 2, 3, or 4 that are upstream from the amino terminal side of a protease cleavage site or a species homolog or chemical analogue thereof in a pharmaceutically acceptable carrier compatible with administration to a patient by a specified route of administration.
A method for enhancing or maintaining effector function of an antibody administered to a patient for the treatment of a pathological condition, wherein the antibody is subject to cleavage by one or more proteases in the patient, which method comprises vaccinating the patient before, after or concurrently with the antibody treatment, with a human IgG protease cleavage site peptide capable of generating antibodies that bind to the treatment antibody and can restore effector function thereto.
Dependencies are inferred from the claim text.